Perioperative Intravenous Glutamine Supplemetation in Major Abdominal Surgery for Cancer A Randomized Multicenter Trial

Department of Surgery, Milano-Bicocca University, S. Gerardo Hospital, Monza, Italy.
Annals of surgery (Impact Factor: 7.19). 10/2009; 250(5):684-90. DOI: 10.1097/SLA.0b013e3181bcb28d
Source: PubMed

ABSTRACT To investigate whether perioperative intravenous glutamine supplementation may affect surgical morbidity.
Small-sized randomized trials showed a trend toward a reduction of postoperative infections in surgical patients receiving glutamine.
: A randomized, multicentre trial was carried out in 428 subjects who were candidates for elective major gastrointestinal surgery. Inclusion criteria were: documented gastrointestinal cancer, weight loss <10% in previous 6 months, and age >18 years. Patients received either intravenous infusion of L-alanine-L-glutamine dipeptide (0.40 g/kg/d; equal to 0.25 g of free glutamine) (Ala-Glu group, n = 212), or no supplementation (control group, n = 216). Glutamine infusion began the day before operation and continued postoperatively for at least 5 days. No postoperative artificial nutrition was allowed unless patients could not adequately eat by day 7. Postoperative morbidity was assessed by independent observers according to a priori definition.
Patients were homogenous for baseline and surgical characteristics. Mean percent of weight loss was 1.4 (2.7) in controls and 1.4 (2.4) in Ala-Glu group. Overall postoperative complication rate was 34.9% (74/212) in Ala-Glu and 32.9% (71/216) in control group (P = 0.65). Infectious morbidity was 19.3% (41/212) in Ala-Glu group and 17.1% (37/216) in controls (P = 0.55). The rate of major complications was 7.5% (16/212) in Ala-Glu group and 7.9% (17/216) in controls (P = 0.90). Mean length of hospitalization was 10.2 days (4.8) in Ala-Glu group versus 9.9 days (3.9) in controls (P = 0.90). The rate of patients requiring postoperative artificial nutrition was 13.2% (28/212) in Ala-Glu group and 12.0% (26/216) in controls (P = 0.71).
Perioperative glutamine does not affect outcome in well-nourished GI cancer patients.

Download full-text


Available from: Luca Gianotti, Dec 28, 2013
  • [Show abstract] [Hide abstract]
    ABSTRACT: Associations between glutamine (Gln) enriched nutrition support and surgical patients with gastrointestinal (GI) tumor remain controversy. The purpose of this meta-analysis was to assess the effect of Gln enriched nutrition support on surgical patients with GI tumor in term of relevant biochemical indices, immune indices, and clinical outcomes. Six databases were systematically searched to find eligible randomized controlled trials (RCTs) from 1966 to May 2014. When estimated the analysis indexes, the relative risk (RR) was used as the effect size of the categorical variable, while the weighted mean difference (MD) was used as the effect size of a continuous variable. Meta-analysis was conducted with Rev Man 5.2. Thirteen RCTs, involving 1034 patients, were included in the meta-analysis. The analysis showed that Gln enriched nutrition support was more effective in increasing serum albumin (MD: 0.10; 95% confidence interval [CI]: 0.02-0.18; P < 0.05), serum prealbumin (MD: 1.98; 95% CI: 1.40-2.55; P < 0.05) and serum transferring (MD: 0.35; 95% CI: 0.12-0.57; P < 0.05), concentration of IgG (MD: 1.26; 95% CI: 0.90-1.63; P < 0.05), IgM (MD: 0.18; 95% CI: 0.11-0.25; P < 0.05), IgA (MD: 0.22; 95% CI: 0.10-0.33; P < 0.05), CD3 + (MD: 3.71; 95% CI: 2.57-4.85; P < 0.05) and CD4/CD8 ratio (MD: 0.27; 95% CI: 0.12-0.42; P < 0.05). Meanwhile, it was more significant in decreasing the incidence of infectious complications (RR: 0.67; 95% CI: 0.50-0.90; P < 0.05) and shortening the length of hospital stay (MD: -1.72; 95% CI: -3.31--0.13; P < 0.05). Glutamine enriched nutrition support was superior in improving immune function, reducing the incidence of infectious complications and shortening the length of hospital stay, playing an important role in the rehabilitation of surgical GI cancer patients.
    Chinese medical journal 01/2015; 128(2):245-51. DOI:10.4103/0366-6999.149219 · 1.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Previously small randomized clinical trials and several meta-analyses have suggested improved patient outcomes from parenteral glutamine supplementation. A recent large multi-center randomized trial conducted in critically ill patients with documented multiple organ failure at enrollment demonstrated an increase in mortality among those receiving supplemental glutamine. This article discusses the discrepancies in trial outcomes and the risks associated with glutamine administration during critical illness.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Secondary to surgery, patients are subjected to metabolic changes and physiological immunosuppression that increase the risk of infection and other postoperative complications. Several ways, included pharmaco-nutrition, could attenuate surgical stress and reduce postoperative morbidity. The postoperative administration of a diet, containing three immuno-nutrients (arginine, nucleotides and fish oil) (Impact®), reduces postoperative morbidity in all types of serious gastrointestinal surgeries. The effect is greater when the product is given pre-and postoperatively. It is noticeable that the effect of immune-nutrition in patients undergoing ERAS techniques has not been investigated. Several studies showed that intravenous form of glutamine (Dipeptiven®) reduces infectious complications and postoperative hospital length of stay. In patient with major postoperative complication receiving parenteral nutrition, glutamine administration is recommended. There is more uncertainty about the clinical effects of intravenous fish oils (EPA and DHA). Most of studies, conducted in small series of patients, showed a tendency to decrease infectious complications and length of stay. Therefore, in patients on parenteral nutrition and with a high-risk of postoperative complications, it is probably indicated to use lipid emulsions containing fish oil. A minimum length of administration is required (at least five days) to expect to have beneficial effects. The use of pharmaco-nutrients must be integrated into an overall management of perioperative patient whose objective is to reduce the postoperative aggression.
    Nutrition Clinique et Métabolisme 05/2014; DOI:10.1016/j.nupar.2014.02.003 · 0.62 Impact Factor